UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of April 2026

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

 

 

On April 1, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued an announcement entitled, “Change of Principal Place of Business in Hong Kong”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

 

 

INDEX TO EXHIBITS

 

Exhibit Number		Exhibit Title
99.1		Announcement dated April 1, 2026

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: April 1, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

 

 

Exhibit 99.1

 

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

 

 

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

 

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

 

The board (the “Board”) of directors (the “Directors”) of Ascentage Pharma Group International (the “Company”) announces that the principal place of business of the Company in Hong Kong has been changed to Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong with effect from April 1, 2026.

 

	By order of the Board
	Ascentage Pharma Group International Dr. Yang
	Dajun
	Chairman and Executive Director

 

Suzhou, People’s Republic of China, April 1, 2026

 

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei and Dr. David SidranskyNote2 and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.

 

Notes:

 

1.	Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

 

2.	Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.